Please login to the form below

Not currently logged in
Email:
Password:

Invega Trinza

This page shows the latest Invega Trinza news and features for those working in and with pharma, biotech and healthcare.

J&J files three-monthly schizophrenia drug in Europe

J&J files three-monthly schizophrenia drug in Europe

The three-monthly version was approved by the FDA as Invega Trinza in May on the back of clinical data showing that the drug was effective, preventing significant return of schizophrenic ... Xeplion/Invega Sustenna is already a big earner for J&J, with

Latest news

  • FDA approves J&J’s schizophrenia drug Invega Trinza FDA approves J&J’s schizophrenia drug Invega Trinza

    The FDA has approved Johnson &Johnson's Invega Trinza (three-month paliperidone palmitate) for schizophrenia. ... Recovery looks different for everyone and the long-term symptom control offered by Invega Trinza can help patients work toward their own

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...

Infographics